Statins represent the most widely prescribed class of drugs worldwide. They convey a distinct protection from cardiovascular pathologies, which are facilitated via both lipid-lowering and anti-inflammatory actions. Myopathies represent the most common side effects, which range from mild muscle pain to life-threatening rhabdomyolyses. The glucocortioid induced leucine zipper protein GILZ has been reported to exhibit distinct anti-infammatory actions. Aim of the project is to test the hypothesis that the induction of GILZ substantially contributes to the desired actions of statins, but that GILZ also plays a role in their undesired effects. The following questions will be answered in order to test the hypothesis:- In which cell types do statins induce GILZ?- What are the mechanisms for GILZ induction?- Does GILZ contribute to the anti-inflammatory actions of statins?- Does GILZ induction facilitate effects of statins on muscle?Answering these questions can substantially contribute to a better understanding of the mechanisms of action of this important class of drugs, but can also help to better understand adverse side effects.
DFG Programme
Research Grants
International Connection
Switzerland
